Effect of HMG-CoA Reductase Inhibition on Vascular Smooth Muscle Cells Extracellular Matrix Production: Role of RhoA

被引:6
|
作者
Palomino-Morales, Rogelio [1 ]
Perales, Sonia [1 ]
Torres, Carolina [1 ]
Linares, Ana [1 ]
Alejandre, Maria J. [1 ]
机构
[1] Univ Granada, Fac Sci, Dept Biochem & Mol Biol 1, Fuentenueva S-N, E-18071 Granada, Spain
关键词
Extracellular matrix; Collagen type I; III; fibronectin; gene expression; smooth muscle cells; RhoA; lovastatin; mevalonate; geranylgeranyl pyrophosphate; 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE; MEVALONATE PATHWAY; IN-VITRO; COLLAGEN; FIBRONECTIN; STATINS; GROWTH; CHOLESTEROL; EXPRESSION; ATHEROSCLEROSIS;
D O I
10.2174/1570161114666160229115553
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cholesterol-lowering effects apart, statins can improve the endothelial function, stabilize the atherosclerotic plaques, decrease the oxidative stress and inflammation and inhibit the thrombogenic response by means of the inhibition of isoprenoids, which serve as lipid attachments for intracellular signaling molecules. We aimed to evaluate whether the effect of statins on RhoA activity mediate extracellular matrix production, particularly affecting collagen type I, in smooth muscle cells (SMCs). Our results showed that lovastatin decreased collagen expression in primary cultured chicken SMCs as determined by incorporation of [H-3]-proline, RT-PCR and immunocytochemistry. This fall was parallel to that found in Rho A activity. Similar results were found when GGTI-298, a RhoA inhibitor, was added to the culture medium. Mevalonate or geranylgeranyl pyrophosphate reverted these effects. In order to elucidate the role of Rho A in these events we transfected the cell line A10 (rat SMCs) with constitutively active (G14V) or dominant negative RhoA (T19N) constructs. The last ones showed similar results regarding collagen production that those stated above in lovastatin treated primary SMC cultures. Constitutively active RhoA transfected cells showed the opposite effects. Next we performed a promoter activity assay to exclude post-transcriptional mechanisms implicated in these studies. We found a similar pattern in col1a2 promoter activity to that found in collagen expression. Our results have demonstrated that statins regulate the activation of RhoA through its isoprenylation, which is crucial for the regulation of extracellular matrix synthesis in SMCs.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 50 条
  • [11] The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
    Gelosa, Paolo
    Cimino, Mauro
    Pignieri, Alice
    Tremoli, Elena
    Guerrini, Uliano
    Sironi, Luigi
    VASCULAR HEALTH AND RISK MANAGEMENT, 2007, 3 (05) : 567 - 577
  • [12] HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9
    Viedt, C
    Shen, WL
    Fei, JW
    Kamimura, M
    Hänsch, GM
    Katus, HA
    Kreuzer, J
    BASIC RESEARCH IN CARDIOLOGY, 2003, 98 (06) : 353 - 361
  • [13] HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9
    Christiane Viedt
    Weili Shen
    Jianwei Fei
    Motohiro Kamimura
    Gertrud M. Hänsch
    Hugo A. Katus
    Jörg Kreuzer
    Basic Research in Cardiology, 2003, 98 : 353 - 361
  • [14] Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture
    Sindermann, JR
    Fan, L
    Weigel, KA
    Troyer, D
    Müller, JG
    Schmidt, A
    March, KL
    Breithardt, G
    ATHEROSCLEROSIS, 2000, 150 (02) : 331 - 341
  • [15] HMG-CoA reductase inhibitors decrease angiotensin-II-induced vascular fibrosis -: Role of RhoA/ROCK and MAPK pathways
    Ruperez, Monica
    Rodrigues-Diez, Raquel
    Blanco-Colio, Luis Miguel
    Sanchez-Lopez, Elsa
    Rodriguez-Vita, Juan
    Esteban, Vanesa
    Carvajal, Gisselle
    Plaza, Juan Jose
    Egido, Jesus
    Ruiz-Ortega, Marta
    HYPERTENSION, 2007, 50 (02) : 377 - 383
  • [16] Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: Comparison with other human cell types
    NegreAminou, P
    vanVliet, AK
    vanErck, M
    vanThiel, GCF
    vanLeeuwen, REW
    Cohen, LH
    BIOCHIMICA ET BIOPHYSICA ACTA-LIPIDS AND LIPID METABOLISM, 1997, 1345 (03): : 259 - 268
  • [17] Survivin regulates intracellular stiffness and extracellular matrix production in vascular smooth muscle cells
    Krajnik, Amanda
    Nimmer, Erik
    Brazzo III, Joseph A.
    Biber, John C.
    Drewes, Rhonda
    Tumenbayar, Bat-Ider
    Sullivan, Andra
    Pham, Khanh
    Krug, Alanna
    Heo, Yuna
    Kolega, John
    Heo, Su-Jin
    Lee, Kwonmoo
    Weil, Brian R.
    Kim, Deok-Ho
    Gupte, Sachin A.
    Bae, Yongho
    APL BIOENGINEERING, 2023, 7 (04)
  • [18] Effects of HMG-CoA reductase inhibition by simvastatin on vascular dysfunction induced by lipopolysaccharide in rats
    Alvarez de Sotomayor, Maria
    Vega, Silvia
    Mingorance, Carmen
    Marhuenda, Elisa
    Dolores Herrera, Maria
    PHARMACOLOGY, 2008, 82 (02) : 89 - 96
  • [19] Effect of PUFAs on extracellular matrix production and remodeling in vascular smooth muscle cell cultures in an atherosclerotic model
    Palomino-Morales, Rogelio
    Jose Alejandre, M.
    Perales, Sonia
    Torres, Carolina
    Linares, Ana
    EUROPEAN JOURNAL OF LIPID SCIENCE AND TECHNOLOGY, 2014, 116 (11) : 1485 - 1495
  • [20] HMG-CoA reductase inhibitor simvastatin mitigates VEGF-induced "inside-out" signaling to extracellular matrix by preventing RhoA activation
    Xu, Hanshi
    Zeng, Lixia
    Peng, Hui
    Chen, Sheldon
    Jones, Jonathan
    Chew, Teng-Leong
    Sadeghi, Mehran M.
    Kanwar, Yashpal S.
    Danesh, Farhad R.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2006, 291 (05) : F995 - F1004